Singapore’s PRECISE program announced a precompetitive collaboration with Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk to analyze data from the PRECISE‑SG100K population study. The agreement will let pharma partners access genomic and plasma proteomics datasets to advance insights into Asian genetics and disease risk. PRECISE will provide whole‑genome and clinical linkage data from a planned 100,000‑participant cohort; partners will contribute analytic resources and support research activities. The initiative aims to fill diversity gaps in genomic research and inform drug discovery for Asian populations. The collaboration signals growing industry interest in population‑scale, region‑specific genomics as companies seek genetically informed pipelines and more representative biomarker discovery.